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ultrasound-mediated gene transfer of Smad7 in rat remnant
kidney.
Background. Transforming growth factor-b (TGF-b) in re-
nal fibrosis has been well studied, but little attention has been
paid to the potential role of TGF-b in the resolution of re-
nal inflammation. We hypothesize that TGF-b exerts its anti-
inflammation properties by stimulating its negative signaling
pathway involving Smad7.
Methods. A rat remnant kidney model was treated with a
doxycycline-regulated Smad7 gene or control empty vector
using an ultrasound-microbubble (Optison)–mediated system.
Smad7 transgene expression within the kidney was tightly con-
trolled by the addition of doxycycline in the daily drinking wa-
ter. All animals were euthanized at week 4 for examination of
inflammatory responses.
Results. Real-time polymerase chain reaction (PCR) and im-
munohistochemistry revealed that gene transfer of Smad7 re-
sulted in a substantial inhibition of interleukin-1b (IL-1b) and
tumor necrosis factor a (TNFa) expression (all P < 0.01 vs. con-
trol). This was associated with the attenuation of histology dam-
age, proteinuria, serum creatinine, and an increase in creatinine
clearance (all P < 0.05). In addition, overexpression of Smad7
significantly inhibited renal inflammation, including ICAM-1,
iNOS, and accumulation of macrophages and T cells in both
glomeruli and tubulointerstitium. Furthermore, gene transfer
of Smad7 also substantially blocked nuclear factor kappa B
(NFjB) activation in the rat remnant kidney (P < 0.01).
Conclusion. TGF-b/Smad7 signaling plays a critical role in
the resolution of renal inflammation in rat remnant kidney
model. Inhibition of NFjB activation is a key mechanism by
which Smad7 suppresses renal inflammation, which suggests a
crosstalk pathway between NFjB and Smad7. The ability of
Smad7 to inhibit renal inflammation indicates that ultrasound-
microbubble–mediated Smad7 gene therapy may represents a
new therapeutic strategy for glomerulonephritis.
Key words: TGF-b signaling, Smad7, renal inflammation, NFjB,
remnant kidney.
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Transforming growth factor-b (TGF-b) is a pleiotropic
cytokine, and is a key mediator in the pathogenesis of re-
nal fibrosis [1]. Recent studies on TGF-b and its signaling
pathway in renal fibrosis are overwhelming. However, lit-
tle attention has been paid to the potential role of TGF-b
in the resolution of renal inflammation. It is known that
TGF-b has a diverse role in stimulating extracellular ma-
trix production and in inhibiting inflammatory response
[2]. While mice that overexpress active human TGF-b1
result in severe renal fibrosis [3], TGF-b knockout mice
exhibit a widespread inflammation, including the kidney
[4]. It is known that TGF-b exhibits its anti-inflammation
properties by inhibiting macrophage activation, cytokine
(IL-1 and TNFa) production, adhesion molecule (ICAM-
1, ELAM-1), and chemokine (MCP-1, IL-8) expression
[2, 5–7]. TGF-b also exhibits its chemotatic effect on neu-
trophils and macrophages [2]. The accumulated knowl-
edge gained through extensive studies in vitro and in vivo,
including TGF-b knockout and transgenic mice, supports
the concept that TGF-b plays a distinct role in tissue scar-
ring and inflammation. Although the role of TGF-b in re-
nal fibrosis is well known, its anti-inflammation activities
in kidney diseases are still poorly understood.
The recent discovery of Smad proteins as intracel-
lular mediators and regulators of TGF-b signaling has
provided important insights into mechanisms that may
determine the specific role of TGF-b in renal inflam-
mation and fibrosis. TGF-b exerts its biological effects
by signaling through type I and type II receptors to ac-
tivate downstream intracellular substrates, Smad2 and
Smad3 [8], which are inhibited by an inhibitory Smad7
[9]. Activation of Smad2 and Smad3 by TGF-b , high glu-
cose, and advanced glycation end products contributes to
extracellular matrix production by mesangial and tubu-
lar cells, which is inhibited by overexpression of Smad7
[10–14]. Overexpression of Smad7 also alleviates urinary
obstruction–mediated renal fibrosis in rats [15, 16]. The
potential role of Smad7 in regulation of inflammatory
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response has been recently explored, but outcomes are
controversial. Blockade of Smad7 restores TGF-b sig-
naling in chronic bowel inflammation [17], while overex-
pression of Smad7 induces apoptosis in kidney cells [18].
Smad7 transgenic expression in T cells prevents renal
injury in anti-glomerular basement membrane (GBM)
glomerulonephritis [19], but enhances antigen-induced
airway inflammation [20]. While we have understood
the TGF-b signaling pathway in renal fibrosis, the role
of TGF-b signaling in antirenal inflammation remains
largely unknown. Thus, the objective in this study is to
explore the potential mechanisms of TGF-b/Smad sig-
naling in the resolution of renal inflammation in a rat
remnant kidney disease by overexpression of a negative
TGF-b signaling regulator, Smad7.
METHODS
Ultrasound-microbubble–mediated gene transfer
of inducible Smad7 into the remnant kidney
A rat remnant kidney disease model was induced in
male Sprague-Dawley rats (220-250 g) by 5/6 nephrec-
tomy according to previously published protocol [21].
All procedures were carried out in accordance with In-
stitutional Guidelines for Animal Care at Baylor Col-
lege of Medicine. Two groups of 6 rats received gene
transfer of 0.3 mL of a mixture of doxycycline-regulated
pTRE-m2Smad7/Tet-on plasmid (Clontech, Palo Alto,
CA, USA) and Optison (Mallinckrodt, St. Louis, MO,
USA) at a ratio of 1:1 (v/v) or the control empty vec-
tors (pTRE + Tet-on + Optison) into the left kidney at
a dose of 15 lg/kidney via the left renal artery. Immedi-
ately after infusion, the remnant kidney was treated with
ultrasound at 1 MHz for 2 minutes, and Smad7 transgene
expression within the kidney was induced by addition of
doxycycline in the daily drinking water (200 lg/mL) as
previously described [15]. In addition, 6 rats underwent a
sham operation consisting of laparotomy and manipula-
tion of the renal pedicles but without damage to the kid-
ney as normal control. All rats were euthanized at week
4, and kidney tissues were collected for RNA and protein
extraction, and were fixed in Methyl Carnoy’s fixative for
histology and immunohistochemistry.
Examination of renal function and blood pressure
Blood samples were collected at day 0 and weeks 2
and 4 for creatinine concentration measurement. Twenty-
four–hour urine samples were collected in metabolic
cages at day 0 and weekly thereafter for the determina-
tion of urinary levels of protein and creatinine excretion.
Urinary protein concentrations were determined us-
ing the Bio-Rad Protein Assay (Bio-Rad Laboratories,
Hercules, CA, USA). Serum and urine creatinine concen-
trations were measured with the standard Jaffe rate reac-
tion. In addition, a weekly measurement of systolic blood
pressure was performed by rat-tail plethysmography us-
ing BP2000 Blood Pressure Analysis SystemTM (Visitech
Systems, Inc., Apex, NC, USA) in conscious rats.
Renal RNA extraction and real-time PCR examination
Total RNA was isolated from the kidney using the
RNAeasy Isolation Kit (Qiagen, Inc., Valencia, CA,
USA) according to the manufacturer’s instructions. Real-
time reverse transcriptase polymerase chain reaction
(RT-PCR) was performed as previously described [22].
Briefly, a real-time PCR was performed using Bio-Rad
iQ SYBR Green supermix with Opticon (MJ Research,
Inc., Waltham, MA, USA), according to manufacturer’s
instructions. One hundred micrograms of total RNA were
reverse transcribed and subjected to PCR as follows:
94◦C for 2 minutes followed by 40 cycles at 94◦C for
15 seconds, 58◦C for 30 seconds, 72◦C for 30 seconds,
with final extension at 72◦C for 10 minutes. Primers used
in this study were: rat ICAM-1, fwd 5′-GGTGAAGT
CTGTCAAACGGGAGAT -3′, rev 5′-GATCATGG
TACAGCACTGTCAGGT -3′; rat TNFa, fwd 5′-ATGA
GCACAGAAAGCATGATCC -3′, rev 5′-GAAGATG
ATCTGAGTGTG -3′; rat IL-1, fwd 5′-TCACTCAT
TGTGGCTGTGGAGAAG -3′, rev 5′-CACACACT
AGCAGGTCGTCATCAT -3′; rat iNOS, fwd 5′-ACC
CTCCTTGTTCAACTCACCTTC -3′, rev 5′-CTAG
AACCTCCAGGCACACAGTTT -3′; and GAPDH, fwd
5′-CCTGGAGAAACCTGCCAAGTATGA -3′, rev 5′-
TTGAAGTCACAGGAGACAACCTGG -3′. Reaction
specificity was confirmed by gel electrophoresis of prod-
ucts after real-time PCR and melting curve analy-
sis. Ratios for IL-1/GAPDH, TNFa/GAPDH, ICAM-1/
GAPDH, and iNOS/GAPDH mRNA were calculated for
each sample and expressed as the mean ± standard errors
of the mean (SEM).
Histology and immunohistochemistry
Changes in renal morphology were examined in
paraffin-embedded sections (4 lm) with hematoxylin
and eosin or periodic acid-Schiff (PAS). T-cell and
macrophage infiltration, IL-1b , ICAM-1, and iNOS ex-
pression, and NFjB activation were determined by
a three-layer immunohistochemistry with monoclonal
antibodies to: (1) total rat leukocytes (OX-1, which recog-
nizes CD45 antigen); (2) macrophages (ED-1, which rec-
ognizes CD68 antigen); (3) T cells (R73, which recognizes
a nonpolymorphic epitope of the ab T cell receptor). In
addition, rabbit polyclonal antibodies to IL-1b , ICAM-1,
iNOS, and p65 or p50 NFjB subunits were also used.
Monoclonal antibodies were generated in our laboratory
from standard cell lines (gifts from Dr. David Nikolic-
Paterson, Monash University, Melbourne, Australia),
while polyclonal rabbit antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Im-
munostaining for OX-1, R73, and ICAM-1 was per-
formed in 2% paraformaldehyde-lysine-periodate fixed
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frozen sections as previously described [23], while detec-
tion of ED-1+ macrophages, IL-1b , iNOS, and NFjB/p50
and p65 subunits were performed in Methyl Carnoy’s
fixed paraffin sections using a microwaved-based antigen
retrieval technique [24]. After being developed with 3,3-
diaminobenzidine, sections were counter-stained with
hematoxylin.
Semiquantitative analyses of
immunohistochemical staining
Total numbers of cells positive for activated NFjB/P65
(as identified by nuclear staining) and OX-1+, R73+,
ED-1+ cells within the glomerulus were counted in 20
consecutive glomeruli and expressed as cells/glomerular
cross-section (gcs). Positive cells in tubulointerstitium
were counted under high-power-field (×40) by means of
a 0.25-mm2 graticule fitted in the eyepiece of the micro-
scope, and expressed as cells per cm2. Percent positive
immunostaining for IL-1b , ICAM-1, and iNOS in the re-
nal cortex (a cross-section of the kidney) was determined
using quantitative Image Analysis System (Optima 6.5;
Media Cybernatics, Silver Spring, MD, USA). Briefly, the
examined areas of the kidney cortex were outlined, the
positive staining patterns were identified, and the percent
positive area in the examined area was then measured.
Data were expressed as percent positive area examined.
All scoring was performed blinded on coded slides.
Statistical analyses
Data from real-time PCR, monoclonal antibody la-
beling in each particular renal area, for experimental,
control, and sham-operated animals were compared us-
ing one-way analysis of variance (ANOVA) with Tukey’s
comparison program from statistical package for social
science (SPSS, Chicago, IL, USA) for Windows.
RESULTS
Effects of Smad7 gene therapy on blood pressure, renal
function, and histology
Ultrasound-mediated Smad7 gene transfer resulted in
a marked increase in Smad7 expression within the kidney
as previously described [15]. Rats treated with Smad7 or
control vectors had similar elevated systolic blood pres-
sure levels (186 ± 5 mm Hg in Smad7 vs. 196 ± 13.5 mm
Hg in control). However, treatment with Smad7 resulted
in a significant reduction of proteinuria (128 ± 23 mg/24-
hour vs. 196 ± 14 mg/24-hour in control, P < 0.05), serum
creatinine (1.88 ± 0.09 mg/dL vs. 2.5 ± 0.03 mg/dL, P <
0.05), and an increase in creatinine clearance (0.98 ±
0.06 mL/min vs. 0.64 ± 0.14 mL/min in control, P <
0.05). Morphologically, control rats developed moder-
ate to severe tubulointerstitial damage, including focal
tubular atrophy, mononuclear cell infiltration, and fibro-
sis (Fig. 1B). In contrast, rats treated with Smad 7 exhib-
ited a relative normal renal histology (Fig.1C).
Fig. 1. Effect of gene transfer of Smad7 on renal histologic damage in
5/6 nephrectomy in rats. (A) Sham-control, showing normal kidney his-
tology. (B) Diseased kidney treated with empty vector controls exhibits
focal severe tubulointerstitial damage, including many mononuclear cell
infiltration and tubulointerstitial fibrosis. (C) Diseased kidney treated
with Smad7 shows that renal histologic damage is prevented. Kidney
sections are stained with PAS. Magnification: ×200.
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OX-1
ED1
R73
Normal Control-treated Smad7-treated
A B C
FED
G H I Fig. 2. Immunohistochemistry shows thatgene transfer of Smad7 inhibits leukocytic
infiltration in the rat remnant kidney. (A–
C) OX-1+ total leukocytes, (D–F) ED1+
macrophages, and (G–I) R73+ T cells in
sham-operated rat kidney (A, D, G), empty
control vector-treated (B, E, H), and Smad7-
treated (C, F, I) kidney. Positive cells are
shown in black. Each panel represents the
staining pattern for groups of 6 rats. Magni-
fication: ×200.
Effects of overexpression of Smad7
on leukocytic infiltration
As shown in Figure 2, rats treated with empty con-
trol vectors developed moderate renal inflammation, as
demonstrated by a marked increase in the number of OX-
1+ leukocytes, ED-1+ macrophages, and R73+ T cells in
both glomeruli and tubulointerstitium, contributing to fo-
cal tubulointerstitial damage. In contrast, gene transfer of
Smad7 blocked leukocytic infiltration. Semiquantitative
analysis showed that overexpression of Smad7 virtually
inhibited OX-1+ leukocytes, ED-1+ macrophages, and
R73+ T cells infiltrating the glomerulus and tubulointer-
stitium (Fig. 3).
Effects of gene transfer of Smad7 on expression of IL-1b,
TNFa, ICAM-1, and iNOS
The effects of Smad7 gene transfer on expression of
proinflammatory cytokines (IL-1b and TNFa), ICAM-
1, and iNOS were determined at the mRNA levels
by quantitative real-time PCR, and at the protein lev-
els by immunohistochemistry. As shown in Figure 4,
compared with sham-operated animals, real-time PCR
demonstrated that mRNA levels of IL-1b , TNFa, and
iNOS were significantly up-regulated in rats treated with
control vectors, all of which were significantly inhibited by
Smad7 treatment. Interestingly, treatment with Smad7 re-
sulted in further suppression of the base levels of ICAM-1
mRNA expression (Fig. 4D). This indicates that over-
expression of Smad7 may have effects on endogenous
ICAM-1 synthesis. Similar results were also obtained by
immunohistochemistry, as shown in Figure 5.
Inhibition of NFjB activation is a key mechanism
by which gene transfer of Smad7 inhibits
renal inflammation
Next, we investigated the potential signaling mecha-
nism whereby overexpression of Smad7 inhibits renal
inflammation. It has been reported that angiotensin II in-
duces renal inflammation via the activation of the NFjB
pathway [25]. We thus hypothesize that inhibition of re-
nal inflammation by gene transfer of Smad7 in the rat
remnant kidney disease may be associated with blockade
of NFjB activation. As shown in Figure 6, immunohis-
tochemistry revealed that the NFjB/p65 (Fig. 6A to C),
but not the p50 subunit (Fig. 6D to F), was markedly ac-
tivated, as evident by its nuclear location in the areas of
severe tubulointerstitial damage (Fig. 6B). In contrast,
remnant kidneys treated with gene transfer of Smad7 vir-
tually blocked NFjB/p65 activation (Fig. 6C, G, H). Strik-
ingly, activation of NFjB/p65 was highly associated with
severe vascular proliferative inflammation and sclerosis
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Fig. 3. Semiquantification of leukocytic in-
filtration in the rat remnant kidney. (A–C)
Glomerular leukocytic infiltration, and (D–
F) tubulointerstitial leukocytic infiltration
for OX-1+ total leukocytes (A, D), ED1+
macrophages (B, E), and R73+ T cells (C,
F) in sham-operated rat kidney (open bars),
empty control vector-treated (solid bars), and
Smad7-treated (hatched bars) kidney. Each
bar represents the mean ± SEM for a group
of 6 rats. ∗∗P < 0.01, ∗∗∗P < 0.001.
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Fig. 4. Real-time PCR shows that gene trans-
fer of Smad7 inhibits IL-1b, TNFa, iNOS, and
ICAM-1 mRNA expression in the rat remnant
kidney. Total kidney RNA extracted from
sham-operated rats (open bars), empty con-
trol vector-treated (solid bars), and Smad7-
treated (hatched bars) rats were examined by
real-time PCR for (A) IL-1b , (B) TNFa, (C)
iNOS, and ICAM-1 levels. Each bar repre-
sents the mean ± SEM for a group of 6 rats.
∗P < 0.05, ∗P < 0.01, and ∗∗P < 0.001; ns, not
significant.
(Fig. 7). A set of serial sections demonstrated that activa-
tion of NFjB/65 in severe proliferative vascular lesions
was associated with up-regulation of IL-1b (Fig. 7B vs.
E), contributing to macrophage accumulation (Fig. 7H).
In contrast, treatment with Smad7 completely inhibited
vascular NFjB activation (Fig. 7C), IL-1b expression
(Fig. 7F), and the development of vascular inflammation
(Fig. 7I).
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Fig. 5. Immunohistochemistry shows that gene transfer of Smad7 in-
hibits IL-1b, iNOS, and ICAM-1 protein expression in the rat remnant
kidney. Kidney sections from sham-operated rats (open bars), empty
control vector-treated (solid bars), and Smad7-treated (hatched bars)
rats were stained with antibodies against (A) IL-1b , (B) iNOS, and (C)
ICAM-1 and quantitated using a quantitative Image Analysis System
as described in Methods. Each bar represents the mean ± SEM for a
group of 6 rats. ∗P < 0.05 and ∗∗∗P < 0.001; ns, not significant.
DISCUSSION
This study provides evidence that the ultrasound-
mediated disruption of gas-filled microbubbles can
transfect a naked DNA plasmid containing a doxycycline-
inducible Smad7gene into the kidney, and that the
induction of Smad7 transgene expression can block renal
inflammation and progressive renal injury in a rat rem-
nant kidney model. Furthermore, we also demonstrated
that inhibition of NFjB activation and NFjB-dependent
inflammatory response is a key mechanism by which over-
expression of Smad7 suppresses renal inflammation in rat
remnant kidney disease.
It is now well accepted that TGF-b plays a pivotal role
in renal fibrosis. However, little attention has been paid
to the potential role of TGF-b in the resolution of renal
inflammation. Furthermore, the underlying mechanisms
whereby TGF-b exhibits the “dark side” of tissue scarring
and the “bright side” of anti-inflammation remain largely
unclear. This is important since it is impossible to de-
velop effective therapeutic strategies by targeting TGF-b
without better understanding of the essential intracellu-
lar mechanisms of TGF-b and the interplay between the
TGF-b pathway and other inflammatory pathways in tis-
sue scarring and inflammation. We and other investiga-
tors have previously shown that blockade of the TGF-b
signaling pathway by overexpression of Smad7 can in-
hibit renal fibrosis in a rat obstructive kidney disease in
vivo [15, 16]. In addition, overexpression of Smad7 is able
to inhibit collagen matrix expression by mesangial cells
and tubular cells in response to TGF-b [11, 12], high glu-
cose [13], and advanced glycation end products [14] in
vitro. In the present study, we further demonstrated that
gene transfer of Smad7 can also prevent renal inflamma-
tion in a rat remnant kidney model, including inhibition
of proinflammatory cytokines (IL-1b and TNFa), adhe-
sion molecule (ICAM-1), iNOS, and prevention of total
leukocyte, macrophage, and T-cell infiltration. These sup-
pressive effects of Smad7 are consistent with the known
role of TGF-b in anti-inflammation [2]. Indeed, TGF-b
is known to suppress T-cell and macrophage activation,
and expression of a variety of inflammation cytokines,
adhesion molecules, chemokines, and mediators, includ-
ing IL-1, TNFa, ICAM-1, ELAM-1, IL-8, and iNOS [2,
5–7]. However, the intracellular mechanism(s) whereby
TGF-b signals to exert its inhibitory role in inflamma-
tion remains unknown. The ability of overexpression of
Smad7 to inhibit the development of renal inflammation
in a rat remnant kidney disease suggests that Smad7 may
be a critical signaling pathway by which TGF-b functions
to suppress renal inflammation. This is also consistent
with the finding that transgenic overexpression of Smad7
on T cells prevents anti-GBM glomerulonephritis in mice
[19], although overexpression of Smad7 has also been re-
ported to increase bowel and airway inflammation [17,
20].
CONCLUSION
What is a mechanism of Smad7 to inhibit renal inflam-
mation in the rat remnant kidney disease? The present
finding of blocking NFjB activation within the remnant
kidney by overexpression of Smad7 is consistent with
previous observations that blockade of angiotensin II at-
tenuates renal fibrosis and inflammation by suppressing
NFjB activation and macrophage infiltration in rat rem-
nant kidney [25–27]. Thus, inhibition of NFjB activa-
tion may be one mechanism by which gene transfer of
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Fig. 6. Immunohistochemistry shows that
gene transfer of Smad7 inhibits NFjB/p65 ac-
tivation in the rat remnant kidney. Kidney
sections from (A, D) sham-operated rats, (B,
E) empty control vector-treated, and (C, F)
Smad7-treated rats were stained with anti-
bodies against (A–C) NFjB/p65 and (D–F)
p50 subunits and quantitated using quanti-
tative a quantitative Image Analysis System
as described in Methods. Note that numer-
ous NFjB/p65+ cells (dark black nuclei) are
evident in empty (B) control vector-treated
kidney, which is completely inhibited by gene
transfer of (C) Smad7. In contrast, there are
no obvious changes in NFjB/p50 subunit in
sham, control vector, or Smad7-treated ani-
mals (D, E). Semiquantitation of p65 subunit
in both glomeruli and tubulointerstitium is
shown in (G) and (H). Each bar represents
the mean ± SEM for a group of 6 rats. ∗P <
0.05 and ∗∗P < 0.01. Magnification: ×250.
NFκB
/p65
IL-1β
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Normal Control-treated Smad7-treated
Fig. 7. Immunohistochemistry shows that
gene transfer of Smad7 inhibits vascular
NFjB/p65 activation, IL-1b expression, and
macrophage accumulation in severe vascular
proliferative lesions in the rat remnant kid-
ney. Kidney sections from (A, D, G) sham-
operated rats, (B, E, H) empty control vector-
treated, and (C, F, I) Smad7-treated rats
were stained with antibodies against (A–C)
NFjB/p65, (D–F) IL-1b , and (G–I) ED-1. A
set of serial sections (B, E) from empty con-
trol vector-treated kidney shows that marked
vascular (v) NFjB/p65 activation (B, dark
black nuclei) is associated with strong expres-
sion of IL-1b (E), resulting in severe prolif-
erating vascular damage with much ED1+
macrophage accumulation (H). In contrast,
Smad7 treatment completely blocks vascu-
lar NFjB/p65 activation (C), IL-b expression,
and prevents macrophage accumulation (I).
Magnification: ×400.
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Fig. 8. The proposed cross-talk pathway of
TGF-b/Smad7 and NFjB. Activation of the
TGF-b signaling pathway can result in the ex-
pression of inhibitory Smad7. This inhibitory
Smad appears to act by specifically inhibit-
ing Smad2 and Smad3 phosphorylation via
the negative-feedback loop to inhibit the fi-
brogenic effect of TGF-b . On the other hand,
Smad7 may increase IkBa (a NFjB inhibitor)
expression in response to TGF-b , thereby in-
hibiting NFjB activation and inflammatory
response.
Smad7 inhibits renal inflammation in a rat remnant kid-
ney model. The finding of a putative NFjB regulatory
site in the mouse Smad7 promoter reveals a structural
link between the NFjB and Smad7 [28]. In addition, ex-
pression of NFjB/p65 subunit is able to inhibit the Smad7
promoter activity, and this inhibition could be reversed by
coexpression of its inhibitor IkBa [28, 29]. These findings
further support the physiologic relationship between the
TGF-b/Smad7 and NFjB signaling pathways. Therefore,
as shown in Figure 8, our hypothesis is that the cross-
talk between Smad7 and the NFjB cascades is a key
signaling pathway of TGF-b/Smad7 in the resolution of
renal inflammation. However, the precise mechanisms of
the cross-talk between TGF-b/Smad7 signaling and the
NFjB cascades remain largely unclear and will require
further investigation.
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